Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4753451 | 0.81 | KDM4E (0.49) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL4583626 | 0.81 | AOC3 (0.61) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL6318439 | 0.80 | MEN1 (0.52) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL20660983 | 0.80 | AOC3 (0.62) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL6665120 | 0.80 | ADRB2 (0.37) | KDM4EMEN1KMT2ASMN1; SMN2TYR | |
| SCHEMBL6320706 | 0.79 | KDM4E (0.54) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL6320678 | 0.79 | KDM4E (0.57) | KDM4EMEN1KMT2ASMN1; SMN2AOC3 | |
| SCHEMBL23040664 | 0.74 | KDM4E (0.53) | KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23040663 | 0.74 | KDM4E (0.53) | KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1935709 | 0.74 | RAB9A (0.47) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869788-B2 | DNA encoding novel D-aminoacylase and process for producing D-amino acid by using the same | MITSUI CHEMICALS, INC. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1472260-A2 | THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040116464-A1 | Aryl-ethanolamine derivatives as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-17 | — | — | US | disclosed |
| EP-1365023-A1 | DNA ENCODING NOVEL D-AMINOACYLASE AND PROCESS FOR PRODUCING D-AMINO ACID BY USING THE SAME | Mitsui Chemicals, Inc. (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207436-A1 | Dna encoding novel d-aminoacylase and process for producing d-amino acid by using the same | MITSUI CHEMICALS, INC. (JP) | 2003-11-06 | — | — | US | disclosed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | KDM4E 1156/4885MEN1 1462/4885KMT2A 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.